{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:28:56Z","timestamp":1779362936762,"version":"3.51.4"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.msard.2021.102778","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T21:35:13Z","timestamp":1611783313000},"page":"102778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals"],"prefix":"10.1016","volume":"50","author":[{"given":"Alexey","family":"Boyko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8845-811X","authenticated-orcid":false,"given":"Christina","family":"Therapontos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Horakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarmila","family":"Szilasiov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Kalni\u0146a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Kolontareva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Gross-Paju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Selmaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ieva","family":"Sereike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Milo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-7187","authenticated-orcid":false,"given":"Tereza","family":"Gabeli\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uro\u0161","family":"Rot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.msard.2021.102778_bib0001","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1212\/WNL.0b013e31824528c9","article-title":"Association of MRI metrics and cognitive impairment in radiologically isolated syndromes","volume":"78","author":"Amato","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102778_bib0002","unstructured":"ATLAS of MS (MS international Federation) \u2013 Third Edition, September 2020. Available at https:\/\/www.atlasofms.org (Assessed on 16 November 2020)."},{"key":"10.1016\/j.msard.2021.102778_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418759189","article-title":"Management of multiple sclerosis patients in central European countries: current needs and potential solutions","volume":"11","author":"Berger","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"10","key":"10.1016\/j.msard.2021.102778_bib0005","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1177\/1352458518782005","article-title":"Neurofilaments and 10-year follow-up in multiple sclerosis","volume":"24","author":"Bhan","year":"2018","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2021.102778_bib0006","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/aian.AIAN_345_18","article-title":"Can we treat secondary progressive multiple sclerosis Now?","volume":"22","author":"Bhatia","year":"2019","journal-title":"Ann. Indian Acad. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2021.102778_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026421","article-title":"Multiple challenges for people after transitioning to secondary progressive multiple sclerosis: a qualitative study","volume":"9","author":"Bogosian","year":"2019","journal-title":"BMJ Open"},{"issue":"2_suppl","key":"10.1016\/j.msard.2021.102778_bib0009","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1352458517708668","article-title":"New insights into the burden and costs of multiple sclerosis in Europe: results for Russia","volume":"23","author":"Boyko","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102778_bib0010","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fneur.2019.00261","article-title":"Cognitive impairment in multiple sclerosis with regards to disease duration and clinical phenotypes","volume":"10","author":"Brochet","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2021.102778_bib0011","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2147\/NDT.S173280","article-title":"Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study","volume":"14","author":"Cai","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.msard.2021.102778_bib0012","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archneurol.2011.765","article-title":"Large, nonplateauing relationship between clinical disability and cerebral white matter lesion load in patients with multiple sclerosis","volume":"69","author":"Caramanos","year":"2012","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2021.102778_bib0013","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1212\/WNL.59.5.679","article-title":"Benefit of interferon beta-1a on MSFC progression in secondary progressive MS","volume":"59","author":"Cohen","year":"2002","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2021.102778_bib0014","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1474-4422(13)70233-3","article-title":"Body fluid biomarkers in multiple sclerosis","volume":"13","author":"Comabella","year":"2014","journal-title":"Lancet Neurol."},{"issue":"Pt 3","key":"10.1016\/j.msard.2021.102778_bib0015","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awl007","article-title":"Natural history of multiple sclerosis: a unifying concept","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2021.102778_bib0016","article-title":"Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies","volume":"4","author":"Coret","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"3","key":"10.1016\/j.msard.2021.102778_bib0017","first-page":"527","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"Correale","year":"2017","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.msard.2021.102778_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007674","article-title":"You are just left to get on with it': qualitative study of patient and carer experiences of the transition to secondary progressive multiple sclerosis","volume":"5","author":"Davies","year":"2015","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.msard.2021.102778_bib0019","first-page":"93","article-title":"Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis","volume":"87","author":"De Stefano","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9139","key":"10.1016\/j.msard.2021.102778_bib0020","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.msard.2021.102778_bib0021","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/ene.13236","article-title":"Survey of diagnostic and treatment practices for multiple sclerosis in Europe","volume":"24","author":"Fernandez","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2021.102778_bib0022","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/ene.13581","article-title":"Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: progressive MS, paediatric MS, pregnancy and general management","volume":"25","author":"Fernandez","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2021.102778_bib0023","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ana.21436","article-title":"Gray matter atrophy in multiple sclerosis: a longitudinal study","volume":"64","author":"Fisher","year":"2008","journal-title":"Ann. Neurol."},{"issue":"Pt 3","key":"10.1016\/j.msard.2021.102778_bib0024","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/brain\/awm329","article-title":"Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis","volume":"131","author":"Fisniku","year":"2008","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.msard.2021.102778_bib0025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1155\/2013\/484959","article-title":"Clinical, MRI, and CSF markers of disability progression in multiple sclerosis","volume":"35","author":"Gajofatto","year":"2013","journal-title":"Dis. Markers"},{"issue":"24","key":"10.1016\/j.msard.2021.102778_bib0026","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1212\/01.wnl.0000264890.97479.b1","article-title":"Predicting short-term disability in multiple sclerosis","volume":"68","author":"Gauthier","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2021.102778_bib0027","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.102778_bib0028","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1148\/radiol.2019190306","article-title":"Atrophied brain T2 lesion volume at MRI is associated with disability progression and conversion to secondary progressive multiple sclerosis","volume":"293","author":"Genovese","year":"2019","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.msard.2021.102778_bib0029","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/1352458513494490","article-title":"Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis","volume":"20","author":"Giorgio","year":"2014","journal-title":"Mult. Scler."},{"issue":"Suppl 1","key":"10.1016\/j.msard.2021.102778_bib0030","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","article-title":"Brain health: time matters in multiple sclerosis","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2021.102778_bib0031","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.102778_bib0032","series-title":"Multiple Sclerosis: Perspectives in Treatment and Pathogenesis. Brisbane","article-title":"Living with Multiple Sclerosis in Europe: pharmacological Treatments, Cost of Illness, and Health-Related Quality of Life Across Countries","author":"Gitto","year":"2017"},{"key":"10.1016\/j.msard.2021.102778_bib0033","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.msard.2018.09.032","article-title":"Multiple sclerosis registries in Europe - an updated mapping survey","volume":"27","author":"Glaser","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9350","key":"10.1016\/j.msard.2021.102778_bib0034","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"issue":"2_suppl","key":"10.1016\/j.msard.2021.102778_bib0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1352458517708117","article-title":"New insights into the burden and costs of multiple sclerosis in Europe: results of the Czech Republic","volume":"23","author":"Havrdova","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102778_bib0036","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.msard.2019.08.003","article-title":"Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech Republic from 2013 to 2016: data from the national registry ReMuS","volume":"35","author":"Horakova","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"14","key":"10.1016\/j.msard.2021.102778_bib0037","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1177\/1352458519848965","article-title":"The MSBase registry: informing clinical practice","volume":"25","author":"Kalincik","year":"2019","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2021.102778_bib0038","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1212\/CON.0000000000000737","article-title":"Phases and phenotypes of multiple sclerosis","volume":"25","author":"Kantarci","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"issue":"2","key":"10.1016\/j.msard.2021.102778_bib0039","first-page":"161","article-title":"Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland","volume":"54","author":"Kapica-Topczewska","year":"2020","journal-title":"Neurol. Neurochir. Pol."},{"issue":"10127","key":"10.1016\/j.msard.2021.102778_bib0040","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"15 Supplement","key":"10.1016\/j.msard.2021.102778_bib0041","doi-asserted-by":"crossref","first-page":"S12.006","DOI":"10.1212\/WNL.92.15_supplement.S12.006","article-title":"A novel functional composite endpoint to characterize disease progression in patients with secondary progressive multiple sclerosis (S12.006)","volume":"92","author":"Kappos","year":"2019","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2021.102778_bib0042","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1177\/1352458514521517","article-title":"Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis","volume":"20","author":"Katz Sand","year":"2014","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2021.102778_bib0043","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1756285617708911","article-title":"MRI in the assessment and monitoring of multiple sclerosis: an update on best practice","volume":"10","author":"Kaunzner","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.msard.2021.102778_bib0044","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1212\/CPJ.0b013e31824cb0ac","article-title":"Practice patterns of US neurologists in patients with SPMS and PPMS: a consensus study","volume":"2","author":"Khan","year":"2012","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.msard.2021.102778_bib0045","series-title":"Time to, and rate of secondary progression in patients with multiple sclerosis: Results of a systematic search","author":"Khurana","year":"2017"},{"issue":"15 Supplement","key":"10.1016\/j.msard.2021.102778_bib0046","doi-asserted-by":"crossref","first-page":"P2.380","DOI":"10.1212\/WNL.90.15_supplement.P2.380","article-title":"Estimated prevalence of secondary progressive multiple sclerosis in the USA and Europe: results from a systematic literature search (P2.380)","volume":"90","author":"Khurana","year":"2018","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2021.102778_bib0047","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"Kobelt","year":"2017","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2021.102778_bib0048","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/jnnp.2010.208173","article-title":"The natural history of secondary progressive multiple sclerosis","volume":"81","author":"Koch","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.msard.2021.102778_bib0049","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.msard.2021.102778_bib0050","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1212\/WNL.0b013e31821432ff","article-title":"Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis","volume":"76","author":"Kuhle","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2021.102778_bib0051","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp-2012-303291","article-title":"Interferon beta for secondary progressive multiple sclerosis: a systematic review","volume":"84","author":"Mantia","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.msard.2021.102778_bib0052","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.tins.2016.02.001","article-title":"Secondary progression in multiple sclerosis: neuronal exhaustion or distinct pathology?","volume":"39","author":"Larochelle","year":"2016","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.msard.2021.102778_bib0053","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis","volume":"9","author":"Lassmann","year":"2018","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.msard.2021.102778_bib0054","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.102778_bib0055","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/1352458513494958","article-title":"Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study","volume":"20","author":"Lavorgna","year":"2014","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2021.102778_bib0056","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/1352458511398371","article-title":"Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study","volume":"17","author":"Le Page","year":"2011","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.msard.2021.102778_bib0057","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/1352458510375707","article-title":"Cognitive function in radiologically isolated syndrome","volume":"16","author":"Lebrun","year":"2010","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2021.102778_bib0058","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1212\/NXI.0000000000000599","article-title":"Blood neurofilament light chain at the doorstep of clinical application","volume":"6","author":"Leppert","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.102778_bib0059","first-page":"273","article-title":"Disability progression unrelated to relapses in relapsing-remitting multiple sclerosis: insights from the Swiss multiple sclerosis cohort study","author":"Lorscheider","year":"2019","journal-title":"ECTRIMS Online Library"},{"issue":"Pt 9","key":"10.1016\/j.msard.2021.102778_bib0060","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.msard.2021.102778_bib0061","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2021.102778_bib0062","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2021.102778_bib0063","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00401-018-1818-y","article-title":"Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis","volume":"135","author":"Luchetti","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"8","key":"10.1016\/j.msard.2021.102778_bib0064","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1177\/1352458518783667","article-title":"Predicting risk of secondary progression in multiple sclerosis: a nomogram","volume":"25","author":"Manouchehrinia","year":"2019","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2021.102778_bib0065","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1352458514564491","article-title":"A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2021.102778_bib0066","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/1352458514549397","article-title":"Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis","volume":"21","author":"Martinez","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102778_bib0067","unstructured":"Mavenclad\u00ae (cladribine) tablets, EMD Serono, Inc. Highlights of Prescribing Information. March 2019. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022561s000lbl.pdf (Accessed on 31 March 2020)."},{"key":"10.1016\/j.msard.2021.102778_bib0068","unstructured":"Mavenclad\u00ae (cladribine) tablets, Merck Europe B.V. Summary of Product Characteristics. August 2017. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mavenclad-epar-product-information_en.pdf (Accessed on 31 Mar 2020)."},{"key":"10.1016\/j.msard.2021.102778_bib0069","unstructured":"Mayzent\u00ae (siponimod) tablets, Novartis Inc., Highlights of Prescribing Information. March 2019. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209884s000lbl.pdf (Accessed on 31 Mar 2020)."},{"key":"10.1016\/j.msard.2021.102778_bib0070","unstructured":"Mayzent\u00ae (siponimod) tablets, Novartis Europharm Limited. Summary of Product Characteristics. March 2020. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mayzent-epar-product-information_en.pdf (accessed on 31 Mar 2020)."},{"issue":"8","key":"10.1016\/j.msard.2021.102778_bib0071","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s40265-017-0726-0","article-title":"Pharmacological approaches to the management of secondary progressive multiple sclerosis","volume":"77","author":"Nandoskar","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2021.102778_bib0072","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.msard.2018.09.002","article-title":"Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey","volume":"26","author":"Nazareth","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2021.102778_bib0073","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000487329","article-title":"Facing the unknown: fear of progression could be a relevant psychological risk factor for depressive mood states among patients with multiple sclerosis","volume":"87","author":"Nielsen","year":"2018","journal-title":"Psychother. Psychosom."},{"issue":"8","key":"10.1016\/j.msard.2021.102778_bib0074","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1212\/WNL.0000000000001856","article-title":"Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis","volume":"85","author":"Novotna","year":"2015","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.msard.2021.102778_bib0075","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1080\/09638288.2016.1211760","article-title":"The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals","volume":"39","author":"O'Loughlin","year":"2017","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.msard.2021.102778_bib0076","doi-asserted-by":"crossref","DOI":"10.2217\/nmt-2019-0024","article-title":"Diagnosis and management of secondary-progressive multiple sclerosis: time for change","author":"Oh","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"issue":"2_suppl","key":"10.1016\/j.msard.2021.102778_bib0077","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/1352458517708142","article-title":"New insights into the burden and costs of multiple sclerosis in Europe: results for Hungary","volume":"23","author":"Pentek","year":"2017","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2021.102778_bib0078","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40263-016-0340-9","article-title":"Secondary progressive multiple sclerosis: definition and measurement","volume":"30","author":"Plantone","year":"2016","journal-title":"CNS Drugs"},{"issue":"8","key":"10.1016\/j.msard.2021.102778_bib0079","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1212\/WNL.0000000000001281","article-title":"Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis","volume":"84","author":"Radue","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102778_bib0080","unstructured":"RETHINKINGMS IN ROMANIA-A policy Brief. Available at: https:\/\/www.braincouncil.eu\/wp-content\/uploads\/2020\/06\/ROMANIA_DEF_EBC_pp_03122019.pdf (Assessed on 22 November 2020)."},{"issue":"2","key":"10.1016\/j.msard.2021.102778_bib0081","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.nic.2017.01.001","article-title":"MR imaging in monitoring and predicting treatment response in multiple sclerosis","volume":"27","author":"Rio","year":"2017","journal-title":"Neuroimaging Clin. N. Am."},{"key":"10.1016\/j.msard.2021.102778_bib0082","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3389\/fneur.2017.00433","article-title":"The role of T1-weighted derived measures of neurodegeneration for assessing disability progression in multiple sclerosis","volume":"8","author":"Rocca","year":"2017","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2021.102778_bib0083","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11940-013-0233-x","article-title":"Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects","volume":"15","author":"Rommer","year":"2013","journal-title":"Curr. Treat. Options Neurol."},{"issue":"4","key":"10.1016\/j.msard.2021.102778_bib0084","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1474-4422(06)70410-0","article-title":"Secondary progressive multiple sclerosis: current knowledge and future challenges","volume":"5","author":"Rovaris","year":"2006","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.102778_bib0085","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ana.20883","article-title":"Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study","volume":"60","author":"Rudick","year":"2006","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.102778_bib0086","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/jnnp-2012-304333","article-title":"Onset of secondary progressive phase and long-term evolution of multiple sclerosis","volume":"85","author":"Scalfari","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"11","key":"10.1016\/j.msard.2021.102778_bib0087","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/WNL.56.11.1496","article-title":"Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results","volume":"56","year":"2001","journal-title":"Neurology"},{"issue":"2_suppl","key":"10.1016\/j.msard.2021.102778_bib0088","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/1352458517708666","article-title":"New insights into the burden and costs of multiple sclerosis in Europe: results for Poland","volume":"23","author":"Selmaj","year":"2017","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.msard.2021.102778_bib0089","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","article-title":"Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study","volume":"12","author":"Selmaj","year":"2013","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2021.102778_bib0090","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.msard.2014.04.004","article-title":"Continuous prediction of secondary progression in the individual course of multiple sclerosis","volume":"3","author":"Skoog","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2021.102778_bib0091","article-title":"Disease-modifying therapies in multiple sclerosis in Latin America","volume":"3","author":"Skromne-Eisenberg","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"3","key":"10.1016\/j.msard.2021.102778_bib0092","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/WCO.0000000000000096","article-title":"New management algorithms in multiple sclerosis","volume":"27","author":"Sorensen","year":"2014","journal-title":"Curr. Opin. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.102778_bib0093","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jnnp-2018-319129","article-title":"Learning ability correlates with brain atrophy and disability progression in RRMS","volume":"90","author":"Sormani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2021.102778_bib0094","doi-asserted-by":"crossref","first-page":"e636","DOI":"10.1212\/NXI.0000000000000636","article-title":"An argument for broad use of high efficacy treatments in early multiple sclerosis","volume":"7","author":"Stankiewicz","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2021.102778_bib0095","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/1352458512443092","article-title":"Neurofilaments as biomarkers in multiple sclerosis","volume":"18","author":"Teunissen","year":"2012","journal-title":"Mult. Scler."},{"issue":"10130","key":"10.1016\/j.msard.2021.102778_bib0097","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.msard.2021.102778_bib0096","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"15 Supplement","key":"10.1016\/j.msard.2021.102778_bib0098","doi-asserted-by":"crossref","first-page":"P2.393","DOI":"10.1212\/WNL.90.15_supplement.P2.393","article-title":"Predictors of conversion to secondary progressive multiple sclerosis in patients with relapsing\u2013remitting multiple sclerosis (P2.393)","volume":"90","author":"Tomic","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2021.102778_bib0099","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/1352458507084264","article-title":"Natural history of secondary-progressive multiple sclerosis","volume":"14","author":"Tremlett","year":"2008","journal-title":"Mult. Scler."},{"issue":"20","key":"10.1016\/j.msard.2021.102778_bib0100","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1212\/WNL.0b013e3181c1e44f","article-title":"Impact of multiple sclerosis relapses on progression diminishes with time","volume":"73","author":"Tremlett","year":"2009","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2021.102778_bib0101","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"Cree","year":"2019","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2021.102778_bib0102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135886","article-title":"Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction","volume":"10","author":"Vagberg","year":"2015","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.msard.2021.102778_bib0103","first-page":"210","article-title":"A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis","volume":"101","author":"van de Wyngaert","year":"2001","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.msard.2021.102778_bib0104","doi-asserted-by":"crossref","first-page":"40","DOI":"10.17116\/jnevro201811808240","article-title":"Primary-progressive multiple sclerosis in Russia: a medical-sociological study involving patients and neurologists","volume":"118","author":"Vlasov","year":"2018","journal-title":"Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova"},{"key":"10.1016\/j.msard.2021.102778_bib0105","unstructured":"Wilsdon T., Barron A., Mitchell-Heggs A., Ginoza S., 2014. Access to medicines for multiple sclerosis: challenges and opportunities. CRA Project No. D19380. Available at: https:\/\/www.crai.com\/sites\/default\/files\/publications\/CRA-Biogen-Access-to-MS-Treatment-Final-Report.pdf (Assessed on 31 March 2020)."},{"issue":"5","key":"10.1016\/j.msard.2021.102778_bib0106","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1212\/WNL.0000000000004885","article-title":"Effects of physical comorbidities on disability progression in multiple sclerosis","volume":"90","author":"Zhang","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102778_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101861","article-title":"A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: physicians\u2019 and patients\u2019 views","volume":"38","author":"Ziemssen","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2021.102778_bib0108","doi-asserted-by":"crossref","first-page":"e16932","DOI":"10.2196\/16932","article-title":"A physician-completed digital tool for evaluating disease progression (Multiple Sclerosis Progression Discussion Tool): validation study","volume":"22","author":"Ziemssen","year":"2020","journal-title":"J. Med. Internet Res."},{"issue":"13","key":"10.1016\/j.msard.2021.102778_bib0109","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1177\/1352458516629769","article-title":"A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients","volume":"22","author":"Zivadinov","year":"2016","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821000444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821000444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:55:24Z","timestamp":1761900924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821000444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":107,"alternative-id":["S2211034821000444"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102778","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102778"}}